Part three of a series. We did consumer AI first because the anxiety was loudest, fintech second because the opportunity was least understood. We are doing healthtech third because almost everyone gets this category wrong and the prize for getting it right is the largest of the three.
The reflex says healthtech is hard. The reflex is right and wrong.
For fifteen years, Indian healthtech has been structurally hard. Telemedicine ran into unit economics that did not work at scale. Pharmacy apps competed away their margins on a commoditised SKU set. Health insurance lived inside opaque sales channels that no software layer fully fixed. Hospital chains needed patience that most venture capital did not have. The 2021 boom inflated valuations the 2023 reset took back down. A lot of good founders took the shot; the structural realities held them back.
The reflex this produced is “healthtech is too hard in India. Skip the category.” That reflex is right about the playbook of the last decade and badly wrong about the next one. The shape of the opportunity has changed in five specific ways that almost no one has internalised.
First, the infrastructure caught up. The Ayushman Bharat Digital Mission now has 760 million health accounts and ABHA IDs are being linked across hospitals, diagnostics, and pharmacies. The second phase, rolling through 2026, mandates cloud-first data sharing and ABHA integration for any hospital larger than 50 beds. The interoperability layer that took the United States twenty years to half-build, India is shipping in five.
Second, the economics caught up. Continuous glucose monitors crossed below 3,000 rupees per sensor in 2025. Whole genome sequencing dropped below 200 dollars in 2026 thanks to government-backed Biopharma SHAKTI investments. Wearable BP monitors, ECG patches, pulse oximeters, and connected scales are all in the affordable consumer range. The “rich-person tech” of 2020 is now mass-market hardware.
Third, the regulation caught up. 100 percent FDI in insurance opened up annuity and outcome-based product design. The DPDP Act formalised health data consent. IRDAI’s 2025 framework allowed embedded and parametric health insurance. The CDSCO software-as-medical-device guidelines clarified what an AI clinical tool can and cannot claim. These are not perfect rules, but they are real rules, and ambiguous regulation has historically been the single biggest blocker for Indian healthtech.
Fourth, the AI got useful. AI radiology, AI pathology, ambient clinical scribing, voice-driven triage, and decision support for the GP are all crossing usable thresholds in 2026. Qure.ai and Niramai are exporting Indian-built diagnostic AI globally. AIIMS deployed AI research centres across 22 campuses. The Indian government has put more than a billion dollars behind AI in healthcare. This was not the situation eighteen months ago.
Fifth, the capital noticed the asset-light hospital model. The Indian asset-light hospital services market is growing at roughly 30 percent CAGR. Single-specialty chains in IVF, oncology, and nephrology pulled in 1.4 billion dollars in PE in the last 24 months. HCG raised 425 crore in FY26 alone to expand precision oncology. The era of building a 500-crore multispecialty hospital and waiting fifteen years for ROI is being replaced by smaller, focused, high-throughput models.
Put it together and India in 2026 has the digital backbone, the affordable hardware, the workable rules, the credible AI, and the new asset-light playbook. None of those existed at once before. The ideas below are the products to build on top of that stack.
A note before the list. Healthtech rewards depth in one place and punishes generalism. Most of these ideas are not “platforms”; they are care companies, clinical products, or operationally heavy businesses. We have tried to be specific about which is which. The teams that win in this category are typically two-founder pairs where one founder is a real clinician or operator and the other is a real builder. If you do not have the clinician half of the team, fix that before you raise.
If you are building one of the twenty below, or a sharper version of one, come talk to us.
1. The next India pharmacy
Tata 1mg, Apollo 24/7, PharmEasy, Netmeds. The first wave built distribution, then ran into thin margins on a commoditised SKU set. The next pharmacy is not a delivery business; it is a care relationship that happens to dispense medicine.
Build a pharmacy that knows the patient. The wedge is chronic disease cohorts: hypertensives, diabetics, post-MI patients, asthmatics. Each customer is on three to seven prescriptions for years. The product is a subscription that includes the medication, an adherence layer, monthly check-ins with a pharmacist, refill orchestration synced to the doctor visit, and proactive flags when something is off. Margins compound through retention, not through paid acquisition.
Why now: ABHA integration means the pharmacy can see the actual prescription history, not just the current refill. Connected devices feed back vitals. The retention curve of a chronic patient is dramatically longer than the average e-commerce buyer.
Who wins: a pharmacist or clinician founder paired with a strong consumer product team. Operators who have run an actual pharmacy chain, not generic D2C founders.
Watch-outs: do not chase the entire pharmacy market. The acute one-time customer (a course of antibiotics) is unprofitable. Pick the chronic patient and build the loyalty engine specifically for them.
2. Diagnostics-first health membership
Tata 1mg, Healthians, Redcliffe, and Apollo Diagnostics each do millions of tests a year. The customer relationship ends when the report is delivered. The result sits in WhatsApp, gets shown to a GP once, and disappears. The next product treats diagnostics as the start of the relationship, not the end.
Build a diagnostics-led health membership. Annual or quarterly subscription that includes a baseline panel, longitudinal tracking, a personal health doctor who reads the results, lifestyle and supplement recommendations, and a clear escalation path if something is off. The bet is that 8 to 12 percent of users will discover something actionable in any given year, and the product becomes the trusted layer between the user and the clinical system.
Why now: lab automation has driven test prices down 60 to 80 percent in five years. CGMs, ECGs, and at-home blood draws make the data flow continuous, not episodic. ABHA-linked records make longitudinal tracking possible for the first time.
Who wins: a founder who can run both the operational lab side and the clinical content side. A pure consumer founder gets the experience right but fails at the lab cost structure. A pure lab founder fails at retention.
Watch-outs: do not become an insurance product by accident. Selling membership that pays for tests blurs into insurance regulation. Stay clearly on the wellness and prevention side or get an insurance licence.
3. Women’s health, expanded beyond PCOS
Women’s health in India has historically meant maternity (the institutional model) or PCOS (the recent D2C wave). Both leave huge gaps. The full lifecycle of an Indian woman, from puberty through fertility planning through menopause through bone health and cardiovascular care in her 50s and 60s, is not served by a single trusted product.
Build a women’s health platform that follows the user across decades. Adolescent care (PCOS screening, mental health, contraception). Pre-conception and fertility planning. Pregnancy and postpartum, but as a longitudinal product, not a one-time event. Perimenopause and menopause (Indian women experience menopause five to seven years earlier than Western cohorts; the data and the products are both inadequate). Bone, thyroid, and cardiovascular care in later decades. Each life stage is a different product feature; the platform is the relationship.
Why now: women’s health has become a real venture category in 2025 and 2026. Maven, Tia, and Hertility in the US have proven the model. India needs the version that handles the joint family, in-law, and clinical access realities that Western products ignore.
Who wins: a female founder pair with deep credibility, ideally one a clinician (gynaecologist or endocrinologist) and one a consumer builder.
Watch-outs: do not market as “wellness.” Indian women are sophisticated consumers of clinical care and are insulted by wellness-light positioning. Lead with clinical credibility.
4. The IVF and fertility chain, reimagined
The Indian fertility market is roughly 1.5 billion dollars and growing at 18 to 20 percent CAGR. Indira IVF runs 140-plus centres. Nova IVF, Birla Fertility, and ART have scaled. The category is consolidating, but the patient experience remains medieval. Couples spend 2 to 8 lakh per cycle, often for two or three cycles, with success rates that vary wildly and almost no transparency.
Build an IVF and fertility chain that competes on outcomes and experience, not on advertising. Standardise the protocol. Publish honest cycle success rates per age cohort. Use AI in embryo selection and ovarian stimulation protocols (early evidence shows materially improved live-birth rates). Include the male-factor workup as default, not afterthought. Bundle psychological care across the brutal emotional arc.
Why now: AI in embryo selection (companies like Alife, Embryonics, and Avenir genetics) has moved from research to deployment. Indian fertility patients are increasingly digital-native and informed; the days of patriarchal “trust the doctor” are ending.
Who wins: a clinician (reproductive endocrinologist) plus a strong operator. This is a clinic chain, not a software business.
Watch-outs: do not race to scale by adding low-quality clinics. The category’s reputation is fragile, and one botched cycle that goes viral on Instagram can damage the brand for a decade.
5. Pediatric primary care, redesigned
Indian families spend hundreds of thousands of rupees on schooling, then take their child to the GP next door for everything from a fever to a developmental concern. The pediatric primary care layer is fragmented, often staffed by general practitioners with limited pediatric training, and rarely longitudinal. The Indian middle class will pay for better.
Build a pediatric primary care company. Physical clinics in residential dense pockets of tier 1 cities, complemented by a digital layer. Pediatricians, not GPs. Vaccinations, developmental milestone tracking, behavioural and learning concerns, nutrition, sleep, common illness, and chronic conditions like asthma and allergies. Each child has a longitudinal health record from birth to adolescence. Membership pricing per child.
Why now: tier 1 family incomes have grown materially. Willingness to pay for premium pediatric care is the highest in 20 years. Connected devices (thermometers, otoscopes, etc.) reduce visit friction.
Who wins: a pediatrician with operator instincts paired with a consumer product founder.
Watch-outs: clinic-led healthtech needs real estate discipline and per-clinic unit economics that work standalone. Do not subsidise clinics with venture money expecting later monetisation. Each clinic must pay back in 24 to 36 months.
6. Mental health for kids and teens
The mental health crisis among Indian children and adolescents is real and largely invisible. School counsellors are under-resourced, parents are reluctant to engage, and the clinical system has almost no infrastructure for this cohort. Suicide is now the leading cause of death for Indian adolescents in many states. The category exists in research papers and almost nowhere as a product.
Build a clinical mental health product for Indian children and adolescents aged 8 to 18. School partnerships as the primary distribution. Trained clinicians (paediatric psychologists and psychiatrists) doing structured CBT, family therapy, and crisis intervention. AI-supported screening to identify at-risk kids. Parent and teacher coaching. Crisis pathways including suicidal ideation protocols. This is a clinical operation with a software layer, not the reverse.
Why now: post-pandemic mental health awareness in Indian schools jumped substantially. The CBSE 2024 advisory on mental health screening created institutional demand. AI-supported triage and clinician productivity tools are finally credible.
Who wins: a clinical child psychologist who has run a real practice, paired with a B2B founder who can sell to school networks. School distribution is half the product.
Watch-outs: child mental health is the highest-stakes category in this list. Build the clinical governance, supervision, and escalation pathways before you build growth. One avoidable adverse event sets the category back five years.
7. AI-driven home healthcare
Portea pioneered home healthcare in India a decade ago and the category has plateaued. The reasons are operational, not demand-side. Skilled nursing supply is tight, scheduling is messy, and quality varies hugely. AI can fix most of the operational pain that has held the category back, while demand is structurally accelerating as the over-60 population reaches 150 million.
Build an AI-native home healthcare company. The product is two halves. The B2C half handles post-operative recovery, chronic care, elderly care, palliative care, and physiotherapy at home. The B2B half is the operational AI: scheduling, route optimisation, real-time triage of nurse-to-clinical-supervisor escalations, electronic documentation that flows back to the hospital and insurer, and predictive analytics on patient deterioration. The latter is what makes the former actually work at scale.
Why now: voice-driven documentation finally works in Indian languages, removing a major time sink for home health nurses. Connected monitoring devices stream into the platform. The over-60 cohort is at structural scale.
Who wins: an operator who has run a home health business and seen the operational failure modes, paired with a strong AI engineering team.
Watch-outs: do not over-index on the consumer brand. The actual moat is the operational software and the nurse network. Companies that spent on brand and skimped on ops never crossed the chasm.
8. Vision and dental for Bharat
Lenskart proved the model for vision and is now valued accordingly. Clove and Toothsi have made early progress in dental. Both categories are massively underpenetrated in tier 2, tier 3, and rural India. Vision: roughly half of Indians who need glasses do not have them. Dental: only 1 percent of India’s 5 lakh dentists practise in tier 2 and below.
Build a vision or dental chain designed for Bharat from day one. Smaller-format clinics in tier 2 and tier 3 cities. Lower price points, payment plans, group discounts via employers and government schemes. Telehealth backbone for triage and follow-up. Standardised protocols. Use vans or pop-up camps to reach district headquarters that cannot support a permanent clinic.
Why now: the Lenskart playbook validated that the consumer optical category is large enough. Government and employer-funded health schemes increasingly cover vision and dental basics. Last-mile logistics in tier 2 and 3 has improved substantially through Delhivery, Ecom Express, and Shadowfax.
Who wins: a founder who has built a chain in any consumer category and understands tier 2 unit economics. Healthcare-only founders typically underestimate retail.
Watch-outs: each clinic must be standalone-profitable within twelve months. Do not let a few showcase clinics in metros fool you into believing the model works. Tier 2 is the test.
9. Teledermatology with AI triage
Indian dermatology runs on two tracks. The metro track is over-supplied with cosmetic-led clinics. The tier 2 and rural track is starved; the average district has fewer than ten qualified dermatologists. Skin conditions including acne, eczema, fungal infections, and chronic dermatoses affect tens of millions, and most never see a specialist. Tele-derm is the obvious answer and has been attempted, but never well.
Build an AI-augmented tele-dermatology company. The user uploads images. An AI model trained on Indian skin tones (note: most existing models are not) generates a preliminary triage. A qualified dermatologist reviews and confirms within hours. Treatment plan, prescription, and over-the-counter product recommendations follow. Recurring follow-up via the app. Distribution through GP networks and pharmacies in tier 2.
Why now: image-based dermatology models calibrated to Indian skin tones have started shipping in 2025. The cost of a tele-consult is finally below what a tier 2 family will pay out of pocket.
Who wins: a dermatologist co-founder is non-negotiable. The other co-founder needs a strong consumer product or AI background.
Watch-outs: do not become a pharmacy in disguise. The temptation to push high-margin OTC products will compromise clinical trust. The product is the diagnosis and the relationship; the medication is the side effect.
10. AI radiologist for tier 2 and 3
India has roughly 15,000 trained radiologists serving 1.4 billion people. The shortage is acute in tier 2 and 3, where many small hospitals run imaging machines without a full-time radiologist; films get sent to a metro radiologist with a 24 to 72 hour turnaround. AI-assisted radiology has been the most clinically validated application of medical AI globally and the time-to-deploy in India is now.
Build a teleradiology and AI radiology product targeted at tier 2 and 3 hospitals and diagnostic centres. The AI flags critical findings (intracranial bleeds, pulmonary embolism, fractures) in real time. A network of radiologists reviews and signs off remotely with workflow optimisation. Critical findings escalate within minutes; routine reads come back within hours. Pricing per study or per month, with hospital integration via DICOM.
Why now: Qure.ai and a handful of others have already proven the FDA, EU, and India regulatory pathway. India’s 22-campus AIIMS AI deployment validates clinical credibility. Hospitals in tier 2 are actively shopping for the integrated stack.
Who wins: a radiologist plus a strong machine learning team. The clinical workflow nuance matters more than the model.
Watch-outs: liability is the entire business. A missed cancer or a missed bleed is a career-ending event. Build clinical governance, escalation pathways, and second-read protocols from day one.
11. AI pathologist for cancer screening
Cervical, breast, and oral cancer screening at scale in India is gated by the shortage of trained cytopathologists. Government programmes have tried to deploy screening; the bottleneck is reading the slides. AI for pathology image analysis has matured to the point of clinical viability, and India is a natural deployment ground.
Build an AI-pathology company focused on cancer screening at population scale. Partner with diagnostic chains, public health programmes, and tier 2 hospitals. Slides are digitised once and read by AI in minutes, with pathologist sign-off for positives. The economic model can support population-level screening that human-only workflows never could. The wedge can be cervical (HPV-driven, well-validated AI), breast (mammography and FNAC), or oral (smartphone-camera-based screening for high-risk cohorts including tobacco users).
Why now: digital pathology hardware costs collapsed in the last 36 months. AI accuracy in specific cancer types has crossed pathologist parity in published trials. The government’s cancer-screening push is creating institutional demand.
Who wins: a pathologist or oncologist plus a strong AI team. Distribution requires relationships with public health systems.
Watch-outs: regulatory clearance for autonomous AI diagnosis is not yet there in India. Design as “AI-assisted pathologist sign-off” not “AI alone.” Get the CDSCO classification right at the start.
12. The doctor copilot for OPD
Indian outpatient practice runs on three-minute consultations and handwritten prescriptions. Doctors lose 30 to 40 percent of their time to documentation, prescription writing, follow-up reminders, and basic patient communication. None of this is value-added clinical work. AI ambient scribing, prescription generation, and patient communication tools, calibrated for Indian languages and the actual OPD workflow, are a massive opportunity.
Build a doctor copilot product. Voice-driven ambient documentation that listens to the consultation, extracts the clinical note, generates the prescription in the doctor’s preferred format, and pushes the follow-up reminder to the patient. Multilingual (Hindi, Tamil, Telugu, Marathi, Bengali, plus English). Integrates with the doctor’s existing EMR or replaces it for solo practitioners. Pricing per doctor per month.
Why now: voice transcription in Indian languages crossed clinical utility in 2025. Indian doctors are willing buyers; international scribing tools (Abridge, Augmedix, Suki) have validated the global appetite. The Indian market needs the local-language and local-format version.
Who wins: a founder pair where one is a practising physician (the product depth is non-trivial) and the other is a strong AI or product founder.
Watch-outs: do not bolt on too many features. The best version of this is ruthlessly focused on saving doctor time. Adoption is the only metric that matters. Engagement KPIs are misleading.
13. AI for hospital revenue cycle and operations
Indian hospitals lose 15 to 25 percent of their revenue to claims rejection, denied insurance reimbursements, missed billing, and operational inefficiency. Revenue cycle management software in the US is a multi-billion-dollar category (Waystar, R1 RCM, Olive). India has the same problem with much weaker software.
Build a hospital RCM and ops platform. Claims-aware billing that pre-checks insurance policies in real time. Pre-authorisation workflows that talk to TPAs directly. Denial management with AI that pulls the exact regulatory or contractual reason and pushes for resubmission. OT and bed-management optimisation. Discharge summary generation. Pricing as a percentage of additional revenue recovered.
Why now: ABHA-driven interoperability removes a major data plumbing problem. The IRDAI claims framework standardised in 2025 reduces the integration burden. Hospitals are facing margin compression and are actively shopping.
Who wins: a B2B founder with hospital sales experience, paired with a strong product and engineering team. Selling to Indian hospitals is a known hard problem; you cannot fake the relationship layer.
Watch-outs: the sales cycle is brutal. Plan a 9 to 12 month enterprise sales cycle. Founders who promised three-month sales got embarrassed.
14. PBM and corporate health benefits
Indian employers spend roughly 25,000 crore annually on corporate health insurance and employee wellness. The category is dominated by traditional brokers (Marsh, Aon, Plum) and a handful of digital first movers (Plum, Onsurity). Nobody has built the actual PBM (pharmacy benefit manager) and care navigation layer that the US matured 30 years ago. The Indian employer is ready for it.
Build a PBM and benefits product. Integrate with the employer’s insurance broker. Negotiate pharmacy and diagnostic prices across the employee base. Steer employees to high-quality providers with transparent pricing. Manage chronic care for high-cost employees (diabetes, mental health, cardiovascular). Telehealth and second opinion. Reporting back to the employer on cost trend and outcomes.
Why now: 100 percent FDI in insurance has changed insurer behaviour around outcome-based deals. Large Indian employers (TCS, Infosys, Reliance, the major banks) are actively asking for this product after seeing US PBM models.
Who wins: a founder pair with deep insurance or PBM domain knowledge plus enterprise sales. Plum and Onsurity will compete; the wedge is depth on care navigation, not just insurance.
Watch-outs: PBMs in the US are deeply problematic businesses with serious conflicts of interest. The Indian version has the chance to do this honestly. Lead with transparency or you become the thing you should not become.
15. Precision oncology and genomic testing
Whole genome sequencing crossed below 200 dollars per genome in India in 2026. NGS is moving from rare-disease and tertiary cancer into routine practice. Hospitals like HCG raised 425 crore in FY26 specifically to expand precision oncology infrastructure. The Indian NGS market is projected to hit 1.33 billion dollars by 2033.
Build a precision oncology and genomic testing company. The product is the diagnostic and the interpretation layer combined. Tumour profiling for actionable mutations, germline testing for hereditary cancer, pharmacogenomics for chemotherapy dose optimisation, and minimal residual disease monitoring. The pricing is per-test plus a recurring layer for longitudinal monitoring. Distribution through oncologist networks at the major hospital chains.
Why now: government Biopharma SHAKTI investments cut the cost of sequencing. CDSCO clearance for several NGS panels landed in 2025 and early 2026. Oncologists are increasingly trained to act on molecular results, having historically been more conservative.
Who wins: an oncologist or molecular biologist with deep clinical credibility, paired with a strong commercial founder. The hard part is convincing oncologists to use the test and act on the result, not the sequencing itself.
Watch-outs: do not build only the diagnostic without the interpretation. A raw NGS report sent to an oncologist who cannot read it is worse than no report. The interpretation and treatment recommendation layer is the actual product.
16. Cancer care navigation
A cancer diagnosis triggers a chaotic two-to-five-year journey across oncologists, surgeons, radiation centres, chemotherapy infusions, palliative care, and increasingly genomics. Indian patients lose months to coordination failures, wrong sequencing of treatments, and second opinions that come too late. The category in the US has spawned companies like Color Health (now valued at over 1.5 billion) and Thyme Care. India has nothing equivalent.
Build a cancer care navigation company. The product is a clinical and operational layer between the patient and the fragmented system. Care coordinator (clinically trained) assigned per patient. Treatment plan review by a tumour board. Second opinion access to leading oncologists. Logistics support (travel, accommodation, financial counselling). Insurance and claims handling. Continuous symptom tracking and chemo side-effect support. Genomic and clinical trial matching where relevant.
Why now: the Indian cancer incidence is rising sharply, with 1.5 million new cases annually. Employer interest in offering this as a benefit has materialised in 2025 and 2026. Insurance companies are interested in the cost-savings story.
Who wins: an oncologist or oncology-care veteran with credibility, plus a strong consumer or B2B founder depending on go-to-market.
Watch-outs: this is heavy operational work, not a software business. The team has to be willing to be in the trenches with patients. Founders who underestimate that have failed.
17. The asset-light hospital chain
The classic 500-crore multispecialty hospital has been a poor venture investment for two decades. The new model, validated by Indian PE in the last 24 months, is the asset-light single-specialty chain. IVF (Indira IVF), cardiac (Asian Heart, KIMS), oncology (HCG), and renal (NephroPlus) have all shown the model works. The category is growing at roughly 30 percent CAGR.
Build a single-specialty hospital chain. Pick one specialty that is high volume, standardisable, and not already dominated. Strong candidates: ENT and audiology, ophthalmology surgery (cataract is at 75 million annual procedures globally), orthopaedic day-care (knee and hip), pain management, and gastroenterology. Asset-light means leased real estate, capex-efficient equipment, and protocol-driven clinical work. Replicable per-clinic unit economics within 18 to 30 months.
Why now: tier 1 and tier 2 demand is structurally there. PE money is actively chasing the model. The clinical talent supply has grown enough to staff replicable chains.
Who wins: a clinician with proven operating chops (someone who has run a hospital or clinic chain), paired with a real estate and operations partner.
Watch-outs: standardisation is the entire game. The chain that lets each clinic do things its own way collapses. The team has to be culturally comfortable with protocol-driven medicine, which is hard for some clinicians.
18. Senior and assisted living
India has 150 million people over the age of 60 and the cohort is growing faster than any other age group. Quality senior living and assisted living infrastructure is almost non-existent at scale. Antara, Athulya, and a handful of regional players have made starts; the category is wide open. The diaspora children of Indian seniors, in particular, are a high-willingness-to-pay buyer.
Build a senior and assisted living business. Three tiers can coexist. Independent living for the active 60-to-75 cohort (community, wellness, light medical). Assisted living for the 75-plus or limited-mobility cohort (more clinical, more nursing). Memory care for cognitive decline. Locations near tier 1 metros but in lower-cost peripheral pockets. Real estate light, operations heavy. The diaspora family is often the financial decision-maker.
Why now: the demographic shift is now undeniable. Diaspora willingness to pay has compounded for a decade. Tier 1 real estate in peripheral areas is acquirable at reasonable cost.
Who wins: an operator with hospitality, geriatric care, or hotel experience. Healthcare-only founders typically underestimate the residential experience side.
Watch-outs: regulatory frameworks for senior living in India are still maturing. Engage early. Trust is the entire business; one neglect or safety incident lands you on prime-time news.
19. Respiratory and allergy care
Roughly 100 million Indians live with chronic asthma, COPD, allergic rhinitis, or related respiratory conditions. Air pollution makes the situation structurally worse. The category is served by GPs, ENT specialists, and pulmonologists in fragmented practices, with no clear branded care company. This is one of the largest unmet chronic care needs in the country.
Build a respiratory and allergy care company. Diagnostic-first (allergy panels, spirometry, FeNO testing where indicated). Specialist consultation. Personalised treatment plans including environmental management, immunotherapy where appropriate, medication regimens, and digital monitoring of symptoms. Subscription-based membership for chronic patients. Bundle pediatric and adult cohorts under one brand. Distribute through schools (asthma screening), employers, and consumer marketing in polluted metros.
Why now: air quality awareness has crossed an inflection point in 2025 and 2026, with multiple Indian cities making global “worst air quality” lists routinely. Immunotherapy availability in India has expanded. Wearable spirometry is consumer-affordable.
Who wins: a pulmonologist or allergist with operating chops, paired with a strong consumer product founder.
Watch-outs: do not become a wellness brand selling air purifiers. The clinical care is the product; air purifier affiliate revenue is a distraction at best, a credibility risk at worst.
20. Wearables and remote patient monitoring
Continuous glucose monitors below 3,000 rupees. ECG patches at 5,000. Wearable BP cuffs that fit on a wrist. Connected scales. Pulse oximeters with cellular connectivity. The hardware is here. The software layer that turns this data into actual clinical decisions, in the right clinician’s hands, at the right time, is barely built in India.
Build a remote patient monitoring company. Two halves again: the consumer-facing side that handles device provisioning, data capture, and patient engagement, and the B2B side that delivers clinically actionable summaries to physicians and triggers escalations when needed. Disease-specific protocols: post-MI cardiac, diabetes, hypertension, post-surgical, pregnancy, chronic kidney disease. Insurance-paid for some cohorts, employer-paid for others, out-of-pocket for the rest.
Why now: the device costs are finally consumer-affordable. ABHA-linked clinical records make integration with the clinical workflow possible. Insurance and employer demand has materialised. CDSCO has clarified the regulatory pathway for connected health devices.
Who wins: a founder with clinical depth (cardiology or endocrinology ideally), paired with a hardware and integration engineering lead. Distribution through hospital chains, insurance partners, and direct.
Watch-outs: do not be a hardware company. The device is the entry point; the software, the analytics, and the clinical workflow are the product. Founders who fell in love with the device lost the company.
Picking one
Twenty ideas is a menu, not a strategy. Four filters for narrowing.
First, healthtech rewards depth in one place. Every successful Indian healthcare company is recognisable for one specific thing: Apollo for hospitals, Indira for IVF, Tata 1mg for pharmacy delivery, HCG for oncology. The companies that tried to be three things at once almost always lost. Pick one. Do it better than anyone else for five years before adding the second thing.
Second, the clinical co-founder is the product. Healthtech is the only category where the founder’s credibility with the medical community is sometimes more important than the product. A doctor founder builds trust ten times faster than a consumer founder. If your team does not have a clinician co-founder with real practice depth, fix that first. Hiring a medical advisor is not the same.
Third, regulation is not a barrier; it is a moat. The teams that engage with CDSCO, IRDAI, IRDAI, and the relevant medical councils early and seriously end up with a multi-year regulatory advantage. The teams that try to “move fast and apologise later” in healthcare hit walls. Indian regulators have remembered the Theranos lesson and are not patient.
Fourth, plan for ten years. Healthtech is a compounding business. Trust compounds. Clinical evidence compounds. Operating excellence compounds. Brand compounds. The teams that get this and the funds that support it patiently are the ones that win. Healthcare graveyards are full of three-year companies trying to be five-year companies.
A final note on the macro. Indian healthtech is at the rare moment where infrastructure (ABDM), capital (asset-light PE), regulation (IRDAI, CDSCO), demographics (aging), and AI capability are all aligned for the first time. Founders who saw 2013 to 2023 as proof that healthtech in India does not work are looking at the wrong data. The next decade rewards different founders, with different playbooks, building different companies. Build accordingly.
We will follow up with what to build in vertical AI SaaS next, then AI infra. If you are building one of the twenty above, or a sharper version of one, we want to hear from you.
The Kae Capital team. June 2026.
A note on intent: this is a thought piece, not an investment thesis. The ideas, categories, and companies discussed here do not necessarily reflect Kae’s active investment positioning or current portfolio. Nothing in this post should be read as a recommendation, solicitation, or commitment to invest. We write to surface ideas worth thinking about and to start conversations with builders, not to telegraph deals.
